Archives
-
DRD4, PI3K/Akt, and Liver Cancer Resistance
2026-09-10
The 2024 British Journal of Cancer study identifies DRD4 as a functional driver of liver cancer stem cell-like traits, chemotherapy resistance, and tumorigenicity rather than merely a prognostic marker. Its mechanistic model places DRD4 upstream of PI3K/Akt/GSK-3β-dependent β-catenin stabilization and nuclear localization, providing a rationale for pathway-focused validation in hepatocellular carcinoma models.
-
Canagliflozin Hemihydrate: Assay Boundaries
2026-09-09
Canagliflozin hemihydrate is a research-grade SGLT2 inhibitor for studying renal glucose reabsorption inhibition and glucose homeostasis. This article develops an assay-boundary framework using recent drug-sensitized yeast evidence to distinguish transporter biology from unsupported mTOR claims.
-
AR/ARv7 Targeting in Triple-Negative Breast Cancer
2026-09-09
The reference study integrates patient immunohistochemistry, TCGA-BRCA analysis, and pharmacological experiments to define AR and ARv7 as clinically relevant features in triple-negative breast cancer. Its MDA-MB-231 data indicate that enzalutamide and EPI-001 suppress metastasis- and epithelial–mesenchymal transition-associated programs, with the ROCK/NF-κB/c-Myc axis emerging as a mechanistic framework for further investigation.
-
Mitochondrial Membrane Potential with JC-1
2026-09-08
Explore how the JC-1 Mitochondrial Membrane Potential Assay Kit connects ΔΨm measurement with neutrophil mitochondrial stress, NETosis, and pathological angiogenesis in bladder cancer. This article emphasizes causal assay design, controls, interpretation limits, and translational relevance.
-
Anti-b, mTOR Signaling, and Hepatic Steatosis
2026-09-08
The reference study identifies Anti-b as a low-molecular-weight compound that reduces diet- and oleic-acid-induced dyslipidaemia and hepatic lipid accumulation in animal and cell models. Its main mechanistic contribution is linking Anti-b activity to reduced mTOR phosphorylation and suppression of the mTOR/PPARγ and mTOR/SREBP1 lipogenic pathways, while also illustrating how multi-model pharmacology can distinguish phenotype rescue from pathway-level effects.
-
Smoothened Signaling and Olfaction in Honeybees
2026-09-07
Guo et al. characterize Smoothened (Smo) in Apis mellifera and connect Hedgehog pathway perturbation with olfactory receptor expression, antennal electrophysiology, and odor-guided behavior. The study provides a useful insect model for examining how pharmacological Smo modulation may influence sensory biology while also defining important limits on translation to mammalian systems.
-
TBST for High-Signal uPAR·uPA Assays
2026-09-07
TBST combines buffered salt conditions with Tween 20 to improve antibody-based detection across Western blotting, immunofluorescence, immunohistochemistry, and immunocytochemistry. This guide connects practical TBST workflows with the conformationally informed uPAR·uPA inhibitor study, while separating assay clarity from mechanistic proof.
-
Cefiderocol Against Resistant European Non-Fermenters
2026-09-05
Henriksen et al. directly compared cefiderocol with recent β-lactam/β-lactamase inhibitor combinations across 1,451 European Pseudomonas aeruginosa and Acinetobacter spp. isolates, including meropenem-resistant subsets. Cefiderocol retained high in vitro susceptibility, while targeted molecular analysis linked resistance mainly to uptake-associated changes; the findings support parallel susceptibility testing but do not replace clinical outcome evidence.
-
Sulfamonomethoxine Toxicity Across Aquatic Species
2026-09-04
Huang and colleagues compared acute and chronic sulfamonomethoxine toxicity across five aquatic organisms spanning algae, cladocerans, and fish. The study’s key contribution is its cross-trophic analysis, which identifies microalgae as particularly sensitive and supports closer evaluation of antibiotic residues in aquaculture effluent.
-
PA–Src–FAK–RhoA/ROCK in Decidualization
2026-09-04
The reference study identifies a phosphatidic acid–Src–FAK–RhoA/ROCK cascade that controls cytoskeletal remodeling during human endometrial stromal-cell decidualization. Its key contribution is to distinguish the morphological arm of decidualization from conventional IGFBP1 and prolactin marker responses, while in vivo uterine experiments support a role for phosphatidic acid in tissue remodeling.
-
Radiotherapy, PD-1/TIGIT Blockade, and CD8+ Memory
2026-09-03
The 2025 Cancer Letters study shows that radiotherapy combined with PD-1 and TIGIT blockade can produce local tumor control, abscopal regression, and durable immune memory in syngeneic mouse models. Its mechanistic contribution is the identification of activated, less-exhausted CD8+ T cells and M1-like macrophage–T-cell communication as key components of this treatment synergy.
-
Red Blood Cell Lysis Buffer for Clean Assays
2026-09-03
Improve mammalian blood sample preparation by removing erythrocytes while retaining nucleated cells for flow cytometry, nucleic acid, and protein workflows. This practical guide connects selective lysis with translational osteoblast research and provides starting parameters, assay-specific controls, and troubleshooting strategies.
-
Bone-Penetrating Copper Nanoassembly and Cuproptosis
2026-09-02
The reference study develops BCB, a baicalein–copper coordinated nanoassembly incorporating a boron-dipyrromethene photosensitizer for combined chemodynamic therapy, photodynamic therapy, and cuproptosis. In melanoma models, the platform enhanced glutathione depletion, reactive oxygen species generation, mitochondrial injury, tumor suppression, and intramedullary tumor accumulation, although its translational value remains limited by preclinical design and light-delivery constraints.
-
DAPI Solution for NETosis and DNA Readouts
2026-09-02
DAPI and 4',6-Diamidino-2-Phenylindole can serve as more than routine nuclear labels in PAD4–NET research. This guide develops a practical assay framework for separating DNA exposure, membrane compromise, nuclear morphology, and mechanism-specific validation in tumor immunology studies.
-
Chloroquine Diphosphate: Flux, Readouts & HBV
2026-09-01
Chloroquine Diphosphate is more than an autophagy inhibitor: it is a strategic flux perturbant for cancer research and HBV-associated innate-immunity studies. This guide connects lysosomal readouts with the 2025 TBK1–HBsAg mechanism to improve assay design and interpretation.